Increased catecholamine excretion after labetalol therapy: a spurious effect of drug metabolites.
Patients with essential hypertension were treated for four weeks with the alpha- and beta-adreno-receptor blocking agent labetalol. Urinary excretion of total catecholamines, metanephrine plus normetanephrine and vanillylmandelic acid was measured with various methods before and during treatment. An unidentified substance interfering with the fluorimetric method for catecholamines and the photometric assay for metanephrines caused falsely high values of those substances. Using appropriate methodology no changes of total catecholamines, metanephrine plus normetanephrine and vanillylmandelic acid excretion were found after labetalol therapy. Our findings are important in preventing errors in the diagnosis of pheochromocytoma as well as in the evaluation of the effects of labetalol on the sympathetic nervous system in man.
D002395:Catecholamines / Q000652:urine*; D004837:Epinephrine / Q000652:urine; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000652:urine; D007741:Labetalol / Q000627:therapeutic use*; D008676:Metanephrine / Q000652:urine; D009638:Norepinephrine / Q000652:urine; D009647:Normetanephrine / Q000652:urine; D014642:Vanilmandelic Acid / Q000652:urine
D002395:Catecholamines; D004983:Ethanolamines; D009647:Normetanephrine; D008676:Metanephrine; D014642:Vanilmandelic Acid; D007741:Labetalol; D009638:Norepinephrine; D004837:Epinephrine